Galectin Therapeutics (GALT) Depreciation & Amortization (CF) (2010 - 2017)
Galectin Therapeutics (GALT) posted quarterly Depreciation & Amortization (CF) of $1000.0 for Q1 2017, little changed year-over-year from $1000.0 in Q1 2016, and down 50.0% quarter-over-quarter from $2000.0 in Q4 2016.
Powered by 
Analysis
Galectin Therapeutics (GALT) Depreciation & Amortization (CF) (2010 - 2017) Analysis & Trends
Galectin Therapeutics' Depreciation & Amortization (CF) history runs 8 years deep, the most recent figure standing at $1000.0 for Q1 2017.
- In Q1 2017, Depreciation & Amortization (CF) changed 0.0% year-over-year to $1000.0; the TTM figure through Dec 2017 stood at $1000.0 (down 85.71% YoY), while the FY2017 annual figure was $1000.0, down 85.71% from the prior year.
- Depreciation & Amortization (CF) for Q1 2017 stood at $1000.0, down from $2000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $3000.0 in Q1 2013, with the low at $1000.0 in Q4 2015.
- The 5-year median for Depreciation & Amortization (CF) is $2000.0 (2014), against an average of $2176.5.
- The sharpest annual moves came in 2013 and 2015: Depreciation & Amortization (CF) jumped 200.0% in 2013, then plunged 50.0% in 2015.
- Galectin Therapeutics' Depreciation & Amortization (CF) stood at $3000.0 in 2013, then plunged by 33.33% to $2000.0 in 2014, then slumped by 50.0% to $1000.0 in 2015, then surged by 100.0% to $2000.0 in 2016, then slumped by 50.0% to $1000.0 in 2017.
- Business Quant data shows GALT's Depreciation & Amortization (CF) at $1000.0 in Q1 2017, $2000.0 in Q4 2016, and $2000.0 in Q3 2016.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Galectin Therapeutics | 304.34 Mn | 304.34 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2017 | 1,000.00 |
| Dec 31, 2016 | 2,000.00 |
| Sep 30, 2016 | 2,000.00 |
| Jun 30, 2016 | 2,000.00 |
| Mar 31, 2016 | 1,000.00 |
| Dec 31, 2015 | 1,000.00 |
| Sep 30, 2015 | 2,000.00 |
| Jun 30, 2015 | 2,000.00 |
| Mar 31, 2015 | 2,000.00 |
| Dec 31, 2014 | 2,000.00 |
| Sep 30, 2014 | 3,000.00 |
| Jun 30, 2014 | 3,000.00 |
| Mar 31, 2014 | 2,000.00 |
| Dec 31, 2013 | 3,000.00 |
| Sep 30, 2013 | 3,000.00 |
| Jun 30, 2013 | 3,000.00 |
| Mar 31, 2013 | 3,000.00 |
| Dec 31, 2012 | 4,000.00 |
| Sep 30, 2012 | 1,000.00 |
| Jun 30, 2012 | 2,000.00 |